DB Biotech Inc.

The DB Biotech in-vitro cloning technology enables the preparation of a pure immunoglobulin fraction corresponding to a single clone of B lymphocytes. The obtained immunoglobulin recognizes only one single linear epitope on the antigen molecule, making a DB Biotech antibody comparable in quality to its monoclonal analogue.

In addition, the influence of the protein tertiary structure – frequently present in epitopes formed during production of monoclonal antibodies – is eliminated in the immunoglobulins corresponding to the clonal antibody. DB Biotech produced antibodies correspond strictly to the conserved linear epitope of the antigen molecule, yielding a higher-quality, more specific antibody with significantly better affinity and avidity.

Founded in 2006, DB Biotech has earned an international reputation for the development of high-quality antibodies used in research and routine clinical diagnostics. DB Biotech‘s goal is to establish a new gold-standard for the development and application of antibodies on a daily basis, from background-free western blots to special quantitative diagnostics, and potential applications of humanized antibodies for disease treatment purposes.